Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Osvaldo Rudy Aren et al.|The Lancet|2019Cited by 3.4k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Gongyan Chen et al.|The Lancet Respiratory Medicine|2020Cited by 508
Current management of chemotherapy-induced neutropenia in adults: key points and new challengesYi Ba, Chenfei Zhou, Yuankai Shi et al.|Cancer Biology and Medicine|2020Cited by 95
miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cellsLin Chen, Jianhua Chang|International Journal of Molecular Medicine|2018Cited by 57
Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathwayChen Lin, Jianhua Chang|Oncotarget|2016Cited by 55